{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:54:57Z","timestamp":1784829297030,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,11]],"date-time":"2013-03-11T00:00:00Z","timestamp":1362960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,5]]},"abstract":"Summary<\/jats:title>Myelofibrosis (MF<\/jats:styled-content>) patients can present with a wide spectrum of disease characteristics. We analysed the consistency of ruxolitinib efficacy across patient subgroups in the CO<\/jats:styled-content><\/jats:styled-content>ntrolled M<\/jats:styled-content>yeloF<\/jats:styled-content>ibrosis Study With OR<\/jats:styled-content><\/jats:styled-content>al JAK<\/jats:styled-content> Inhibitor T<\/jats:styled-content>reatment (COMFORT<\/jats:styled-content>\u2010I,) a double\u2010blind trial, where patients with intermediate\u20102 or high\u2010risk MF<\/jats:styled-content> were randomized to twice\u2010daily oral ruxolitinib (n\u00a0<\/jats:italic>=\u00a0<\/jats:italic>155) or placebo (n\u00a0<\/jats:italic>=\u00a0<\/jats:italic>154). Subgroups analysed included MF<\/jats:styled-content> subtype (primary, post\u2010polycythaemia vera, post\u2010essential thrombocythaemia), age (\u226465, >\u00a065\u00a0years), I<\/jats:styled-content>nternational P<\/jats:styled-content>rognostic S<\/jats:styled-content>coring S<\/jats:styled-content>ystem risk group, baseline E<\/jats:styled-content>astern C<\/jats:styled-content>ooperative O<\/jats:styled-content>ncology G<\/jats:styled-content>roup performance status (0, 1, \u22652), JAK<\/jats:styled-content>2<\/jats:italic> V617F mutation (positive, negative), baseline haemoglobin level (\u2265100, <100\u00a0g\/l), baseline platelet count (100\u2013200\u00a0\u00d7\u00a0109<\/jats:sup>\/l, >200\u00a0\u00d7\u00a0109<\/jats:sup>\/l), baseline palpable spleen size (\u226410, >10\u00a0cm), and baseline quartile of spleen volume and T<\/jats:styled-content>otal S<\/jats:styled-content>ymptom S<\/jats:styled-content>core (TSS<\/jats:styled-content>; Q1\u00a0=\u00a0lowest, Q4\u00a0=\u00a0highest). Mean percentage change from baseline to week 24 in spleen volume and TSS<\/jats:styled-content> were calculated for ruxolitinib and placebo in each subgroup. Overall survival was estimated by K<\/jats:styled-content>aplan\u2013M<\/jats:styled-content>eier method according to original randomization group. In ruxolitinib\u2010treated patients, reductions in spleen volume and TSS<\/jats:styled-content> and evidence of improved survival relative to placebo across subgroups were consistent with those seen in the COMFORT<\/jats:styled-content>\u2010I population, confirming that ruxolitinib is an effective therapy for the spectrum of MF<\/jats:styled-content> patients studied in COMFORT<\/jats:styled-content>\u2010I.<\/jats:p>","DOI":"10.1111\/bjh.12274","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T02:47:33Z","timestamp":1363142853000},"page":"508-516","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo\u2010controlled, Phase III<\/scp> study in patients with myelofibrosis"],"prefix":"10.1111","volume":"161","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Levy","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital University of Toronto Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Catalano","sequence":"additional","affiliation":[{"name":"Frankston Hospital Frankston Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Miller","sequence":"additional","affiliation":[{"name":"Saint Agnes Cancer Institute Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"University of Michigan Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott F.","family":"Winton","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine Atlanta GA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jimmie H.","family":"Harvey","sequence":"additional","affiliation":[{"name":"Birmingham Hematology & Oncology Birmingham AL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat O.","family":"Arcasoy","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute and Duke University Health System Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at The University of Pennsylvania Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Lyons","sequence":"additional","affiliation":[{"name":"Cancer Care Centers of South Texas\/US Oncology San Antonio TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Paquette","sequence":"additional","affiliation":[{"name":"UCLA Medical Hematology & Oncology Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra","family":"Raza","sequence":"additional","affiliation":[{"name":"Columbia Presbyterian Medical Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Vaddi","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Erickson\u2010Viitanen","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sun","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Sandor","sequence":"additional","affiliation":[{"name":"Incyte Corporation Wilmington DE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.782714.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)61026-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_7_9_1","first-page":"411","volume-title":"American Society of Clinical Oncology (ASCO) Education Book","author":"Nguyen H.","year":"2012"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_7_12_1","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS\u20102","volume":"2","author":"Second International Study of Infarct Survival (ISIS\u20102) Collaborative Group.","year":"1988","journal-title":"Lancet"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-315614"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2008.07.002"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-292102"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","unstructured":"Verstovsek S. (2009) Therapeutic potential of JAK2 inhibitors.Hematology\/the Education Program of the American Society of Hematology 636\u2013642.","DOI":"10.1182\/asheducation-2009.1.636"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12274","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:56:18Z","timestamp":1700675778000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,11]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/bjh.12274"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12274","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,11]]},"assertion":[{"value":"2012-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}